Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Cytokinetics Inc’s stock clocked out at $35.9, down -1.99% from its previous closing price of $36.63. In other words, the price has decreased by -$1.99 from its previous closing price. On the day, 1.01 million shares were traded. CYTK stock price reached its highest trading level at $37.09 during the session, while it also had its lowest trading level at $35.86.
Ratios:
To gain a deeper understanding of CYTK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.99 and its Current Ratio is at 5.99.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 24, 2025, initiated with a Overweight rating and assigned the stock a target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.Stifel initiated its Buy rating on January 22, 2025, with a $80 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 22 ’25 when Malik Fady Ibraham sold 2,000 shares for $37.47 per share. The transaction valued at 74,940 led to the insider holds 140,610 shares of the business.
Blum Robert I sold 5,000 shares of CYTK for $190,750 on Jul 14 ’25. The President & CEO now owns 393,108 shares after completing the transaction at $38.15 per share. On Jul 08 ’25, another insider, FADY MALIK, who serves as the Officer of the company, bought 14,000 shares for $33.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4287429376 and an Enterprise Value of 4259676928. For the stock, the TTM Price-to-Sale (P/S) ratio is 223.07. Its current Enterprise Value per Revenue stands at 221.65 whereas that against EBITDA is -7.659.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.65, which has changed by -0.39162856 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $61.27, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 5.56%, while the 200-Day Moving Average is calculated to be -16.92%.
Shares Statistics:
It appears that CYTK traded 1.73M shares on average per day over the past three months and 1163290 shares per day over the past ten days. A total of 119.22M shares are outstanding, with a floating share count of 116.79M. Insiders hold about 2.20% of the company’s shares, while institutions hold 117.07% stake in the company. Shares short for CYTK as of 1752537600 were 15929741 with a Short Ratio of 9.21, compared to 1749772800 on 14005230. Therefore, it implies a Short% of Shares Outstanding of 15929741 and a Short% of Float of 17.4.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Cytokinetics Inc (CYTK) is currently in the spotlight, with 17.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$1.41, with high estimates of -$0.3 and low estimates of -$1.64.
Analysts are recommending an EPS of between -$1.22 and -$6.35 for the fiscal current year, implying an average EPS of -$5.53. EPS for the following year is -$5.41, with 15.0 analysts recommending between -$2.88 and -$7.31.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $88.79M, while the lowest revenue estimate was $1.58M, resulting in an average revenue estimate of $22.66M. In the same quarter a year ago, actual revenue was $18.47MBased on 17 analysts’ estimates, the company’s revenue will be $161.96M in the next fiscal year. The high estimate is $368M and the low estimate is $48.35M.
